http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-H03151358-A

Outgoing Links

Predicate Object
assignee http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_7b4beef0c137d9094e6918ee382be22f
classificationCPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P13-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P15-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D207-09
classificationIPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P9-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P15-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P9-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D207-09
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D207-08
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D207-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P13-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-40
filingDate 1990-10-29-04:00^^<http://www.w3.org/2001/XMLSchema#date>
inventor http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_64a3366c8b3e38a347f585aa2ccd227f
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_496b6e809a58837df872e2c5add70755
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_bb64b43f1c09d1ccf5a260383cb8bb78
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a278c7474578836ef6c621a97331eda2
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_bb06f75926832300959606f8bab9d9d0
publicationDate 1991-06-27-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber JP-H03151358-A
titleOfInvention Benzylpyrrolidine derivative as dopamine agonist
abstract NEW MATERIAL: A compound of formula I [R is H or alkyl; R 1 is H, OH, NH-C(=O)H, -C(=O)NH 2 , NH-C(=O)NH 2 , NHSO 2 R 2 (R 2 is alkyl or optionally substd. phenyl) or halogen; m is 0-6; n is 1-10] and its salt. n EXAMPLE: (R)-2(3,4-Dihydroxybenzyl)1-[5-(N-(3,4dihydroxyphenethyl)-N- propylamino) pentyl] pyrrolidine. n USE: Dopamine agonists useful for treatment of hypertension, congestive heart failure, acute and chronic renal insufficiency, angina, and hyperprolactinemia. n PROCESS: A 2-benzylpyrrolidine of formula II is condensed with an N-(ω- haloalkanoyl)phenethylamine of formula III to give a compound of formula IV, which is then reduced to obtain the compound of formula I. n COPYRIGHT: (C)1991,JPO
priorityDate 1989-10-30-04:00^^<http://www.w3.org/2001/XMLSchema#date>
type http://data.epo.org/linked-data/def/patent/Publication

Incoming Links

Predicate Subject
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID1001
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226399686
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID235112369
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID414427309
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID458394811
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID53928062
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID457574877
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID339556
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID421036711
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226529169
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID410474261
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID122501
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID681

Total number of triples: 39.